2013•European Respiratory JournalRequires access

Usefulness of post bronchodilator FVC in the evaluation and spirometric evolution of COPD patients

Alejandro Raimondi, Alejandro Raimondi

Open publisher page 0 citations

Abstract

Introduction: The rate of decline of forced expiratory volume in 1 second (FEV1) is more increased among chronic obstructive pulmonary disease (COPD) patients with bronchodilator reversibility when compared with those with no response (usually defined by the increase in FEV1). Aims and objectives: We hypothesized that forced vital capacity (FVC) would detect reversibility in more cases than FEV1 and that this finding would correlate with an increased FEV1 decline. Methods: Retrospective analysis of COPD patients evaluated at an outpatient’s clinic between 2005 and 2011. Inclusion criteria were an age between 40 and 80 years, a smoking history of ≥ 10 pack/yrs and 2 years at least of follow-up. Results: 49 patients were included, 8 (16%) had a significant FEV1 increase after bronchodilators, while 19 (39%) showed a significant increase in FVC (Table 1). The mean rate of change in FEV1 was a decline of 50 ml per year. The group of patients with reversibility measured either by FEV1 or FVC had an increased rate of decline of FEV1 compared to those without reversibility (p<0.01). Conclusions: Post bronchodilator FVC detected more reversibility than FEV1 in this COPD patients and seems to be associated with an increased decline in lung function. Table1 Value (total 49) Age, years 68±8 Female sex, % 57 BMI, kg.m-2 23±3 GOLD Stage I, % 8 -Stage II, % 49 -Stage III, % 29 -Stage IV, % 14 Smoking history, pack/year 38±11 Annual change of FEV1, ml/year -50±88 FEV1 reversible group, % 16.3 -Annual change of FEV1, ml/year -142±113 FVC reversible group, % 38.8 -Annual change of FEV1, ml/year -94±86 Data are presented as mean ± SD unless otherwise indicated. BMI: Body mass index.

About this research paper

What this paper is about

Introduction: The rate of decline of forced expiratory volume in 1 second (FEV1) is more increased among chronic obstructive pulmonary disease (COPD) patients with bronchodilator reversibility when compared with those with no response (usually defined by the increase in FEV1). Aims and objectives: We hypothesized that forced vital capacity (FVC) would detect reversibility in more cases than FEV1 and that this finding would correlate with an increased FEV1 decline. Methods: Retrospective analysis of COPD patients evaluated at an outpatient’s clinic between 2005 and 2011. Inclusion criteria were an age between 40 and 80 years, a smoking history of ≥ 10 pack/yrs and 2 years at least of follow-up. Results: 49 patients were included, 8 (16%) had a significant FEV1 increase after bronchodilators, while 19 (39%) showed a significant increase in FVC (Table 1). The mean rate of change in FEV1 was a decline of 50 ml per year. The group of patients with reversibility measured either by FEV1 or FVC had an increased rate of decline of FEV1 compared to those without reversibility (p<0.01). Conclusions: Post bronchodilator FVC detected more reversibility than FEV1 in this COPD patients and seems to be associated with an increased decline in lung function. Table1 Value (total 49) Age, years 68±8 Female sex, % 57 BMI, kg.m-2 23±3 GOLD Stage I, % 8 -Stage II, % 49 -Stage III, % 29 -Stage IV, % 14 Smoking history, pack/year 38±11 Annual change of FEV1, ml/year -50±88 FEV1 reversible group, % 16.3 -Annual change of FEV1, ml/year -142±113 FVC reversible group, % 38.8 -Annual change of FEV1, ml/year -94±86 Data are presented as mean ± SD unless otherwise indicated. BMI: Body mass index.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Introduction: The rate of decline of forced expiratory volume in 1 second (FEV1) is more increased among chronic obstructive pulmonary disease (COPD) patients with bronchodilator reversibility when compared with those with no response (usually defined by the increase in FEV1). Aims and objectives: We hypothesized that forced vital capacity (FVC) would detect reversibility in more cases than FEV1 and that this finding would correlate with an increased FEV1 decline. Methods: Retrospective analysis of COPD patients evaluated at an outpatient’s clinic between 2005 and 2011. Inclusion criteria were an age between 40 and 80 years, a smoking history of ≥ 10 pack/yrs and 2 years at least of follow-up. Results: 49 patients were included, 8 (16%) had a significant FEV1 increase after bronchodilators, while 19 (39%) showed a significant increase in FVC (Table 1). The mean rate of change in FEV1 was a decline of 50 ml per year. The group of patients with reversibility measured either by FEV1 or FVC had an increased rate of decline of FEV1 compared to those without reversibility (p<0.01). Conclusions: Post bronchodilator FVC detected more reversibility than FEV1 in this COPD patients and seems to be associated with an increased decline in lung function. Table1 Value (total 49) Age, years 68±8 Female sex, % 57 BMI, kg.m-2 23±3 GOLD Stage I, % 8 -Stage II, % 49 -Stage III, % 29 -Stage IV, % 14 Smoking history, pack/year 38±11 Annual change of FEV1, ml/year -50±88 FEV1 reversible group, % 16.3 -Annual change of FEV1, ml/year -142±113 FVC reversible group, % 38.8 -Annual change of FEV1, ml/year -94±86 Data are presented as mean ± SD unless otherwise indicated. BMI: Body mass index.

Key concepts: Medicine, COPD, Bronchodilator, Vital capacity, Internal medicine, Lung function, Spirometry, Pulmonary function testing

Related papers

Back to paper searchBrowse research topicsOriginal source
Usefulness of post bronchodilator FVC in the evaluation and spirometric evolution of COPD patients — Research Paper | ScholarLens